The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator ...

Sangamo Therapeutics (SGMO) stock plunged as Pfizer (PFE) ends collaboration on hemophilia A gene therapy. Find out the ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

Sangamo Therapeutics Inc.’s stock tumbled 56% on Tuesday for its second-biggest one-day percentage decline ever, after Pfizer ...

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...

Sangamo Therapeutics Inc. (SGMO) shares plunged in Tuesday's pre-market trading by over 50% after Pfizer Inc. (PFE) ...

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...